Cytosorbents (NASDAQ:CTSO) is a medical technology company focused on developing and commercializing its flagship product, CytoSorb, a blood purification technology aimed at controlling severe inflammation in critically ill and cardiac surgery patients. The technology is designed to filter out inflammatory toxins and substances from the blood to help patients recover from conditions that can lead to organ failure. The company is deeply involved in research and clinical studies to expand the application of CytoSorb for various medical emergencies and conditions, striving to save lives and improve outcomes for critically ill patients. Their objective is to continuously innovate and extend their reach to more patients globally, enhancing the effectiveness of critical care through their advanced treatment options.